TrialDiabetologia2011

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

S L Samson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.